- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Promotes Nathan J. Dowden to President
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada Therapeutics Reports Third Quarter 2023 Financial Results
- Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
- Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
- Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
- Entrada Therapeutics Reports Second Quarter 2023 Financial Results
- Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
More ▼
Key statistics
On Thursday, Entrada Therapeutics Inc (TRDA:NMQ) closed at 12.36, 16.38% above the 52 week low of 10.62 set on May 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.23 |
---|---|
High | 12.58 |
Low | 11.91 |
Bid | 10.50 |
Offer | 14.20 |
Previous close | 12.43 |
Average volume | 77.42k |
---|---|
Shares outstanding | 33.60m |
Free float | 27.64m |
P/E (TTM) | -- |
Market cap | 417.66m USD |
EPS (TTM) | -0.2543 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼